nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—epithelium—Crohn's disease	0.00987	0.0898	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—Crohn's disease	0.00951	0.0865	CbGeAlD
Everolimus—MTOR—skin of body—Crohn's disease	0.00939	0.0854	CbGeAlD
Everolimus—FKBP1A—epithelium—Crohn's disease	0.00888	0.0807	CbGeAlD
Everolimus—MTOR—mammalian vulva—Crohn's disease	0.00856	0.0779	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—Crohn's disease	0.00855	0.0778	CbGeAlD
Everolimus—FKBP1A—skin of body—Crohn's disease	0.00844	0.0768	CbGeAlD
Everolimus—FKBP1A—mammalian vulva—Crohn's disease	0.0077	0.07	CbGeAlD
Everolimus—MTOR—lymphoid tissue—Crohn's disease	0.0076	0.0691	CbGeAlD
Everolimus—MTOR—digestive system—Crohn's disease	0.00751	0.0683	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—Crohn's disease	0.00684	0.0622	CbGeAlD
Everolimus—FKBP1A—digestive system—Crohn's disease	0.00675	0.0614	CbGeAlD
Everolimus—MTOR—lymph node—Crohn's disease	0.00429	0.039	CbGeAlD
Everolimus—FKBP1A—lymph node—Crohn's disease	0.00386	0.0351	CbGeAlD
Everolimus—CYP3A4—digestive system—Crohn's disease	0.00221	0.0201	CbGeAlD
Everolimus—Arthralgia—Mercaptopurine—Crohn's disease	0.00149	0.0025	CcSEcCtD
Everolimus—Fungal infection—Prednisone—Crohn's disease	0.00149	0.0025	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.00148	0.00249	CcSEcCtD
Everolimus—Blood creatinine increased—Mesalazine—Crohn's disease	0.00148	0.00248	CcSEcCtD
Everolimus—Pancreatitis—Azathioprine—Crohn's disease	0.00147	0.00247	CcSEcCtD
Everolimus—Liver function test abnormal—Mesalazine—Crohn's disease	0.00145	0.00245	CcSEcCtD
Everolimus—Dry skin—Mesalazine—Crohn's disease	0.00144	0.00243	CcSEcCtD
Everolimus—Abdominal pain upper—Mesalazine—Crohn's disease	0.00144	0.00242	CcSEcCtD
Everolimus—Oedema—Mercaptopurine—Crohn's disease	0.00143	0.0024	CcSEcCtD
Everolimus—Breast disorder—Mesalazine—Crohn's disease	0.00142	0.00239	CcSEcCtD
Everolimus—Pancytopenia—Azathioprine—Crohn's disease	0.00142	0.00239	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Mesalazine—Crohn's disease	0.00142	0.00239	CcSEcCtD
Everolimus—Nasopharyngitis—Mesalazine—Crohn's disease	0.00141	0.00237	CcSEcCtD
Everolimus—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.0014	0.00235	CcSEcCtD
Everolimus—Gastritis—Mesalazine—Crohn's disease	0.00139	0.00235	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.00139	0.00234	CcSEcCtD
Everolimus—Skin disorder—Mercaptopurine—Crohn's disease	0.00139	0.00233	CcSEcCtD
Everolimus—Endocrine disorder—Prednisone—Crohn's disease	0.00139	0.00233	CcSEcCtD
Everolimus—Abdominal distension—Mesalazine—Crohn's disease	0.00137	0.00231	CcSEcCtD
Everolimus—Acne—Prednisone—Crohn's disease	0.00136	0.0023	CcSEcCtD
Everolimus—Dysphagia—Mesalazine—Crohn's disease	0.00136	0.00229	CcSEcCtD
Everolimus—Influenza—Mesalazine—Crohn's disease	0.00136	0.00229	CcSEcCtD
Everolimus—Anorexia—Mercaptopurine—Crohn's disease	0.00136	0.00229	CcSEcCtD
Everolimus—Pneumonia—Azathioprine—Crohn's disease	0.00134	0.00225	CcSEcCtD
Everolimus—Bronchospasm—Mesalazine—Crohn's disease	0.00134	0.00225	CcSEcCtD
Everolimus—Pancreatitis—Mesalazine—Crohn's disease	0.00134	0.00225	CcSEcCtD
Everolimus—Infestation NOS—Azathioprine—Crohn's disease	0.00133	0.00224	CcSEcCtD
Everolimus—Infestation—Azathioprine—Crohn's disease	0.00133	0.00224	CcSEcCtD
Everolimus—Angina pectoris—Mesalazine—Crohn's disease	0.00133	0.00223	CcSEcCtD
Everolimus—Bronchitis—Mesalazine—Crohn's disease	0.00131	0.0022	CcSEcCtD
Everolimus—Amenorrhoea—Prednisone—Crohn's disease	0.00131	0.0022	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.0013	0.00219	CcSEcCtD
Everolimus—Pancytopenia—Mesalazine—Crohn's disease	0.00129	0.00218	CcSEcCtD
Everolimus—Neutropenia—Mesalazine—Crohn's disease	0.00127	0.00214	CcSEcCtD
Everolimus—Dysuria—Mesalazine—Crohn's disease	0.00127	0.00214	CcSEcCtD
Everolimus—Viral infection—Prednisone—Crohn's disease	0.00127	0.00214	CcSEcCtD
Everolimus—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.00127	0.00213	CcSEcCtD
Everolimus—Hepatobiliary disease—Azathioprine—Crohn's disease	0.00126	0.00212	CcSEcCtD
Everolimus—Pollakiuria—Mesalazine—Crohn's disease	0.00126	0.00212	CcSEcCtD
Everolimus—Decreased appetite—Mercaptopurine—Crohn's disease	0.00124	0.00209	CcSEcCtD
Everolimus—Weight decreased—Mesalazine—Crohn's disease	0.00123	0.00207	CcSEcCtD
Everolimus—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.00123	0.00207	CcSEcCtD
Everolimus—Leukocytosis—Prednisone—Crohn's disease	0.00122	0.00206	CcSEcCtD
Everolimus—Pneumonia—Mesalazine—Crohn's disease	0.00122	0.00205	CcSEcCtD
Everolimus—Infestation—Mesalazine—Crohn's disease	0.00121	0.00204	CcSEcCtD
Everolimus—Infestation NOS—Mesalazine—Crohn's disease	0.00121	0.00204	CcSEcCtD
Everolimus—Hypercholesterolaemia—Prednisone—Crohn's disease	0.00121	0.00204	CcSEcCtD
Everolimus—Cataract—Prednisone—Crohn's disease	0.00121	0.00203	CcSEcCtD
Everolimus—Haemoglobin—Azathioprine—Crohn's disease	0.0012	0.00202	CcSEcCtD
Everolimus—Haemorrhage—Azathioprine—Crohn's disease	0.0012	0.00201	CcSEcCtD
Everolimus—Renal failure—Mesalazine—Crohn's disease	0.00119	0.00201	CcSEcCtD
Everolimus—Stomatitis—Mesalazine—Crohn's disease	0.00118	0.00199	CcSEcCtD
Everolimus—Jaundice—Mesalazine—Crohn's disease	0.00118	0.00199	CcSEcCtD
Everolimus—Urinary tract infection—Mesalazine—Crohn's disease	0.00118	0.00198	CcSEcCtD
Everolimus—Conjunctivitis—Mesalazine—Crohn's disease	0.00118	0.00198	CcSEcCtD
Everolimus—Haematuria—Mesalazine—Crohn's disease	0.00116	0.00195	CcSEcCtD
Everolimus—Hepatobiliary disease—Mesalazine—Crohn's disease	0.00115	0.00193	CcSEcCtD
Everolimus—Epistaxis—Mesalazine—Crohn's disease	0.00115	0.00193	CcSEcCtD
Everolimus—Sinusitis—Mesalazine—Crohn's disease	0.00114	0.00192	CcSEcCtD
Everolimus—Body temperature increased—Mercaptopurine—Crohn's disease	0.00113	0.0019	CcSEcCtD
Everolimus—Skin exfoliation—Prednisone—Crohn's disease	0.0011	0.00184	CcSEcCtD
Everolimus—Haemoglobin—Mesalazine—Crohn's disease	0.0011	0.00184	CcSEcCtD
Everolimus—Rhinitis—Mesalazine—Crohn's disease	0.00109	0.00184	CcSEcCtD
Everolimus—Fluid retention—Prednisone—Crohn's disease	0.00109	0.00183	CcSEcCtD
Everolimus—Hepatitis—Mesalazine—Crohn's disease	0.00109	0.00183	CcSEcCtD
Everolimus—Haemorrhage—Mesalazine—Crohn's disease	0.00109	0.00183	CcSEcCtD
Everolimus—Pharyngitis—Mesalazine—Crohn's disease	0.00108	0.00182	CcSEcCtD
Everolimus—Immune system disorder—Azathioprine—Crohn's disease	0.00108	0.00182	CcSEcCtD
Everolimus—Mediastinal disorder—Azathioprine—Crohn's disease	0.00108	0.00181	CcSEcCtD
Everolimus—Urinary tract disorder—Mesalazine—Crohn's disease	0.00108	0.00181	CcSEcCtD
Everolimus—Oedema peripheral—Mesalazine—Crohn's disease	0.00107	0.00181	CcSEcCtD
Everolimus—Chills—Azathioprine—Crohn's disease	0.00107	0.00181	CcSEcCtD
Everolimus—Connective tissue disorder—Mesalazine—Crohn's disease	0.00107	0.0018	CcSEcCtD
Everolimus—Urethral disorder—Mesalazine—Crohn's disease	0.00107	0.0018	CcSEcCtD
Everolimus—Alopecia—Azathioprine—Crohn's disease	0.00106	0.00178	CcSEcCtD
Everolimus—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00105	0.00177	CcSEcCtD
Everolimus—Pulmonary oedema—Prednisone—Crohn's disease	0.00102	0.00172	CcSEcCtD
Everolimus—Eye disorder—Mesalazine—Crohn's disease	0.00102	0.00171	CcSEcCtD
Everolimus—Cardiac disorder—Mesalazine—Crohn's disease	0.00101	0.0017	CcSEcCtD
Everolimus—Sepsis—Prednisone—Crohn's disease	0.000997	0.00168	CcSEcCtD
Everolimus—Angiopathy—Mesalazine—Crohn's disease	0.000989	0.00166	CcSEcCtD
Everolimus—Immune system disorder—Mesalazine—Crohn's disease	0.000985	0.00166	CcSEcCtD
Everolimus—Mediastinal disorder—Mesalazine—Crohn's disease	0.000982	0.00165	CcSEcCtD
Everolimus—Chills—Mesalazine—Crohn's disease	0.000978	0.00164	CcSEcCtD
Everolimus—Diarrhoea—Mercaptopurine—Crohn's disease	0.000976	0.00164	CcSEcCtD
Everolimus—Ill-defined disorder—Azathioprine—Crohn's disease	0.000967	0.00163	CcSEcCtD
Everolimus—Alopecia—Mesalazine—Crohn's disease	0.000963	0.00162	CcSEcCtD
Everolimus—Anaemia—Azathioprine—Crohn's disease	0.000963	0.00162	CcSEcCtD
Everolimus—Diabetes mellitus—Prednisone—Crohn's disease	0.000958	0.00161	CcSEcCtD
Everolimus—Mental disorder—Mesalazine—Crohn's disease	0.000955	0.00161	CcSEcCtD
Everolimus—Erythema—Mesalazine—Crohn's disease	0.000949	0.0016	CcSEcCtD
Everolimus—Malaise—Azathioprine—Crohn's disease	0.000939	0.00158	CcSEcCtD
Everolimus—Flatulence—Mesalazine—Crohn's disease	0.000935	0.00157	CcSEcCtD
Everolimus—Leukopenia—Azathioprine—Crohn's disease	0.000932	0.00157	CcSEcCtD
Everolimus—Dysgeusia—Mesalazine—Crohn's disease	0.000929	0.00156	CcSEcCtD
Everolimus—Cardiac failure congestive—Prednisone—Crohn's disease	0.000919	0.00155	CcSEcCtD
Everolimus—Back pain—Mesalazine—Crohn's disease	0.000918	0.00154	CcSEcCtD
Everolimus—Muscle spasms—Mesalazine—Crohn's disease	0.000912	0.00153	CcSEcCtD
Everolimus—Vomiting—Mercaptopurine—Crohn's disease	0.000907	0.00153	CcSEcCtD
Everolimus—Rash—Mercaptopurine—Crohn's disease	0.0009	0.00151	CcSEcCtD
Everolimus—Dermatitis—Mercaptopurine—Crohn's disease	0.000899	0.00151	CcSEcCtD
Everolimus—Vision blurred—Mesalazine—Crohn's disease	0.000894	0.0015	CcSEcCtD
Everolimus—Tremor—Mesalazine—Crohn's disease	0.000889	0.0015	CcSEcCtD
Everolimus—Myalgia—Azathioprine—Crohn's disease	0.000887	0.00149	CcSEcCtD
Everolimus—Arthralgia—Azathioprine—Crohn's disease	0.000887	0.00149	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000881	0.00148	CcSEcCtD
Everolimus—Ill-defined disorder—Mesalazine—Crohn's disease	0.00088	0.00148	CcSEcCtD
Everolimus—Anaemia—Mesalazine—Crohn's disease	0.000877	0.00147	CcSEcCtD
Everolimus—Discomfort—Azathioprine—Crohn's disease	0.000876	0.00147	CcSEcCtD
Everolimus—MTOR—Insulin Signaling—SOCS1—Crohn's disease	0.00087	0.00294	CbGpPWpGaD
Everolimus—Angioedema—Mesalazine—Crohn's disease	0.000867	0.00146	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TAB1—Crohn's disease	0.000867	0.00293	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—JAK2—Crohn's disease	0.000857	0.0029	CbGpPWpGaD
Everolimus—Malaise—Mesalazine—Crohn's disease	0.000856	0.00144	CcSEcCtD
Everolimus—Cardiac failure—Prednisone—Crohn's disease	0.000854	0.00144	CcSEcCtD
Everolimus—Syncope—Mesalazine—Crohn's disease	0.000851	0.00143	CcSEcCtD
Everolimus—Lethargy—Prednisone—Crohn's disease	0.000851	0.00143	CcSEcCtD
Everolimus—Leukopenia—Mesalazine—Crohn's disease	0.000849	0.00143	CcSEcCtD
Everolimus—Nausea—Mercaptopurine—Crohn's disease	0.000848	0.00143	CcSEcCtD
Everolimus—Infection—Azathioprine—Crohn's disease	0.000845	0.00142	CcSEcCtD
Everolimus—Palpitations—Mesalazine—Crohn's disease	0.000839	0.00141	CcSEcCtD
Everolimus—Loss of consciousness—Mesalazine—Crohn's disease	0.000834	0.0014	CcSEcCtD
Everolimus—Thrombocytopenia—Azathioprine—Crohn's disease	0.000832	0.0014	CcSEcCtD
Everolimus—Cough—Mesalazine—Crohn's disease	0.000828	0.00139	CcSEcCtD
Everolimus—Skin disorder—Azathioprine—Crohn's disease	0.000826	0.00139	CcSEcCtD
Everolimus—MTOR—B Cell Activation—RASGRP1—Crohn's disease	0.00082	0.00277	CbGpPWpGaD
Everolimus—Hypertension—Mesalazine—Crohn's disease	0.000819	0.00138	CcSEcCtD
Everolimus—MTOR—Interferon type I signaling pathways—STAT3—Crohn's disease	0.000818	0.00277	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—CD79A—Crohn's disease	0.000817	0.00277	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—TYK2—Crohn's disease	0.000813	0.00275	CbGpPWpGaD
Everolimus—Chest pain—Mesalazine—Crohn's disease	0.000808	0.00136	CcSEcCtD
Everolimus—Myalgia—Mesalazine—Crohn's disease	0.000808	0.00136	CcSEcCtD
Everolimus—Arthralgia—Mesalazine—Crohn's disease	0.000808	0.00136	CcSEcCtD
Everolimus—Anxiety—Mesalazine—Crohn's disease	0.000805	0.00135	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000802	0.00135	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—RBX1—Crohn's disease	0.000802	0.00271	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—HSPA1B—Crohn's disease	0.000802	0.00271	CbGpPWpGaD
Everolimus—Discomfort—Mesalazine—Crohn's disease	0.000798	0.00134	CcSEcCtD
Everolimus—Irritability—Prednisone—Crohn's disease	0.000796	0.00134	CcSEcCtD
Everolimus—Hypotension—Azathioprine—Crohn's disease	0.000794	0.00134	CcSEcCtD
Everolimus—MTOR—Immune System—ERAP2—Crohn's disease	0.000794	0.00269	CbGpPWpGaD
Everolimus—Cardiac arrest—Prednisone—Crohn's disease	0.000793	0.00133	CcSEcCtD
Everolimus—MTOR—IRS-related events—TYK2—Crohn's disease	0.00079	0.00268	CbGpPWpGaD
Everolimus—Dry mouth—Mesalazine—Crohn's disease	0.00079	0.00133	CcSEcCtD
Everolimus—FKBP1A—Disease—RSPO3—Crohn's disease	0.00079	0.00267	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—TYK2—Crohn's disease	0.000783	0.00265	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—JAK2—Crohn's disease	0.000783	0.00265	CbGpPWpGaD
Everolimus—MTOR—IRS-mediated signalling—JAK2—Crohn's disease	0.000775	0.00262	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000775	0.0013	CcSEcCtD
Everolimus—Oedema—Mesalazine—Crohn's disease	0.000774	0.0013	CcSEcCtD
Everolimus—Infection—Mesalazine—Crohn's disease	0.000769	0.00129	CcSEcCtD
Everolimus—Dry skin—Prednisone—Crohn's disease	0.000764	0.00129	CcSEcCtD
Everolimus—MTOR—Insulin receptor signalling cascade—TYK2—Crohn's disease	0.000763	0.00258	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—TYK2—Crohn's disease	0.000763	0.00258	CbGpPWpGaD
Everolimus—Shock—Mesalazine—Crohn's disease	0.000762	0.00128	CcSEcCtD
Everolimus—Nervous system disorder—Mesalazine—Crohn's disease	0.000759	0.00128	CcSEcCtD
Everolimus—Hypokalaemia—Prednisone—Crohn's disease	0.000759	0.00128	CcSEcCtD
Everolimus—Thrombocytopenia—Mesalazine—Crohn's disease	0.000758	0.00128	CcSEcCtD
Everolimus—Tachycardia—Mesalazine—Crohn's disease	0.000756	0.00127	CcSEcCtD
Everolimus—MTOR—IRS-related events—JAK2—Crohn's disease	0.000754	0.00255	CbGpPWpGaD
Everolimus—Skin disorder—Mesalazine—Crohn's disease	0.000752	0.00127	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—STAT3—Crohn's disease	0.000752	0.00254	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—IL1B—Crohn's disease	0.00075	0.00254	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SEL1L—Crohn's disease	0.000749	0.00253	CbGpPWpGaD
Everolimus—Hyperhidrosis—Mesalazine—Crohn's disease	0.000749	0.00126	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—JAK2—Crohn's disease	0.000747	0.00253	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—Crohn's disease	0.000742	0.00251	CbGpPWpGaD
Everolimus—Anorexia—Mesalazine—Crohn's disease	0.000738	0.00124	CcSEcCtD
Everolimus—Muscular weakness—Prednisone—Crohn's disease	0.000735	0.00124	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000735	0.00124	CcSEcCtD
Everolimus—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000734	0.00123	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ACKR2—Crohn's disease	0.00073	0.00247	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—JAK2—Crohn's disease	0.000728	0.00246	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—JAK2—Crohn's disease	0.000728	0.00246	CbGpPWpGaD
Everolimus—Abdominal distension—Prednisone—Crohn's disease	0.000725	0.00122	CcSEcCtD
Everolimus—Hypotension—Mesalazine—Crohn's disease	0.000724	0.00122	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CARD9—Crohn's disease	0.000716	0.00242	CbGpPWpGaD
Everolimus—Pancreatitis—Prednisone—Crohn's disease	0.000706	0.00119	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000706	0.00119	CcSEcCtD
Everolimus—MTOR—Oncostatin M Signaling Pathway—STAT3—Crohn's disease	0.000705	0.00239	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—UBE2D1—Crohn's disease	0.000703	0.00238	CbGpPWpGaD
Everolimus—Feeling abnormal—Azathioprine—Crohn's disease	0.000701	0.00118	CcSEcCtD
Everolimus—Insomnia—Mesalazine—Crohn's disease	0.0007	0.00118	CcSEcCtD
Everolimus—MTOR—Cardiac Hypertrophic Response—TNF—Crohn's disease	0.000698	0.00236	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—STAT3—Crohn's disease	0.000697	0.00236	CbGpPWpGaD
Everolimus—Paraesthesia—Mesalazine—Crohn's disease	0.000695	0.00117	CcSEcCtD
Everolimus—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000695	0.00117	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—MLN—Crohn's disease	0.000692	0.00234	CbGpPWpGaD
Everolimus—Dyspnoea—Mesalazine—Crohn's disease	0.00069	0.00116	CcSEcCtD
Everolimus—Somnolence—Mesalazine—Crohn's disease	0.000688	0.00116	CcSEcCtD
Everolimus—Dyspepsia—Mesalazine—Crohn's disease	0.000682	0.00115	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	0.000679	0.0023	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—TYK2—Crohn's disease	0.000676	0.00229	CbGpPWpGaD
Everolimus—Neutropenia—Prednisone—Crohn's disease	0.000674	0.00113	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—TNF—Crohn's disease	0.000674	0.00228	CbGpPWpGaD
Everolimus—Decreased appetite—Mesalazine—Crohn's disease	0.000673	0.00113	CcSEcCtD
Everolimus—Body temperature increased—Azathioprine—Crohn's disease	0.000672	0.00113	CcSEcCtD
Everolimus—Abdominal pain—Azathioprine—Crohn's disease	0.000672	0.00113	CcSEcCtD
Everolimus—FKBP1A—Disease—LTF—Crohn's disease	0.000672	0.00227	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000669	0.00112	CcSEcCtD
Everolimus—Fatigue—Mesalazine—Crohn's disease	0.000668	0.00112	CcSEcCtD
Everolimus—Erectile dysfunction—Prednisone—Crohn's disease	0.000664	0.00112	CcSEcCtD
Everolimus—Constipation—Mesalazine—Crohn's disease	0.000662	0.00111	CcSEcCtD
Everolimus—Pain—Mesalazine—Crohn's disease	0.000662	0.00111	CcSEcCtD
Everolimus—Weight decreased—Prednisone—Crohn's disease	0.000652	0.0011	CcSEcCtD
Everolimus—Hyperglycaemia—Prednisone—Crohn's disease	0.00065	0.00109	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—JAK2—Crohn's disease	0.000645	0.00218	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—Crohn's disease	0.000643	0.00218	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—RIPK2—Crohn's disease	0.00064	0.00217	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—Crohn's disease	0.000638	0.00216	CbGpPWpGaD
Everolimus—Feeling abnormal—Mesalazine—Crohn's disease	0.000638	0.00107	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—TYK2—Crohn's disease	0.000638	0.00216	CbGpPWpGaD
Everolimus—MTOR—Immune System—MADCAM1—Crohn's disease	0.000635	0.00215	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—TYK2—Crohn's disease	0.000634	0.00214	CbGpPWpGaD
Everolimus—Acute coronary syndrome—Prednisone—Crohn's disease	0.000633	0.00107	CcSEcCtD
Everolimus—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000633	0.00107	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TAGAP—Crohn's disease	0.000633	0.00214	CbGpPWpGaD
Everolimus—Myocardial infarction—Prednisone—Crohn's disease	0.00063	0.00106	CcSEcCtD
Everolimus—MTOR—Leptin signaling pathway—STAT3—Crohn's disease	0.000629	0.00213	CbGpPWpGaD
Everolimus—Hypersensitivity—Azathioprine—Crohn's disease	0.000626	0.00105	CcSEcCtD
Everolimus—Abdominal pain—Mesalazine—Crohn's disease	0.000612	0.00103	CcSEcCtD
Everolimus—Body temperature increased—Mesalazine—Crohn's disease	0.000612	0.00103	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—JAK2—Crohn's disease	0.000609	0.00206	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—JAK2—Crohn's disease	0.000605	0.00205	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CXCL8—Crohn's disease	0.000598	0.00202	CbGpPWpGaD
Everolimus—Diarrhoea—Azathioprine—Crohn's disease	0.000582	0.000978	CcSEcCtD
Everolimus—Haemoglobin—Prednisone—Crohn's disease	0.00058	0.000975	CcSEcCtD
Everolimus—Haemorrhage—Prednisone—Crohn's disease	0.000577	0.00097	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—Crohn's disease	0.000574	0.00194	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—STAT3—Crohn's disease	0.000574	0.00194	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICOSLG—Crohn's disease	0.000574	0.00194	CbGpPWpGaD
Everolimus—Hallucination—Prednisone—Crohn's disease	0.000574	0.000965	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—Crohn's disease	0.000573	0.00194	CbGpPWpGaD
Everolimus—Hypersensitivity—Mesalazine—Crohn's disease	0.000571	0.00096	CcSEcCtD
Everolimus—Connective tissue disorder—Prednisone—Crohn's disease	0.000567	0.000953	CcSEcCtD
Everolimus—Dizziness—Azathioprine—Crohn's disease	0.000562	0.000946	CcSEcCtD
Everolimus—Asthenia—Mesalazine—Crohn's disease	0.000556	0.000934	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—RSPO3—Crohn's disease	0.000553	0.00187	CbGpPWpGaD
Everolimus—Pruritus—Mesalazine—Crohn's disease	0.000548	0.000921	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—Crohn's disease	0.000544	0.00184	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—TYK2—Crohn's disease	0.000542	0.00183	CbGpPWpGaD
Everolimus—FKBP1A—Disease—GCKR—Crohn's disease	0.000541	0.00183	CbGpPWpGaD
Everolimus—Vomiting—Azathioprine—Crohn's disease	0.000541	0.000909	CcSEcCtD
Everolimus—Eye disorder—Prednisone—Crohn's disease	0.000539	0.000906	CcSEcCtD
Everolimus—Rash—Azathioprine—Crohn's disease	0.000536	0.000902	CcSEcCtD
Everolimus—Dermatitis—Azathioprine—Crohn's disease	0.000536	0.000901	CcSEcCtD
Everolimus—Flushing—Prednisone—Crohn's disease	0.000535	0.0009	CcSEcCtD
Everolimus—Headache—Azathioprine—Crohn's disease	0.000533	0.000896	CcSEcCtD
Everolimus—Diarrhoea—Mesalazine—Crohn's disease	0.00053	0.000891	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—SEL1L—Crohn's disease	0.000524	0.00177	CbGpPWpGaD
Everolimus—Angiopathy—Prednisone—Crohn's disease	0.000523	0.00088	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NOD1—Crohn's disease	0.000522	0.00177	CbGpPWpGaD
Everolimus—Immune system disorder—Prednisone—Crohn's disease	0.000521	0.000876	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—TYK2—Crohn's disease	0.000519	0.00176	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—JAK2—Crohn's disease	0.000517	0.00175	CbGpPWpGaD
Everolimus—Dizziness—Mesalazine—Crohn's disease	0.000512	0.000861	CcSEcCtD
Everolimus—MTOR—Immune System—DEFA5—Crohn's disease	0.000512	0.00173	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNGR2—Crohn's disease	0.000512	0.00173	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—TYK2—Crohn's disease	0.00051	0.00173	CbGpPWpGaD
Everolimus—Alopecia—Prednisone—Crohn's disease	0.00051	0.000857	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—JAK2—Crohn's disease	0.000509	0.00172	CbGpPWpGaD
Everolimus—Mental disorder—Prednisone—Crohn's disease	0.000505	0.00085	CcSEcCtD
Everolimus—Nausea—Azathioprine—Crohn's disease	0.000505	0.000849	CcSEcCtD
Everolimus—Malnutrition—Prednisone—Crohn's disease	0.000502	0.000844	CcSEcCtD
Everolimus—Erythema—Prednisone—Crohn's disease	0.000502	0.000844	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—Crohn's disease	0.000497	0.00168	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—JAK2—Crohn's disease	0.000495	0.00167	CbGpPWpGaD
Everolimus—Vomiting—Mesalazine—Crohn's disease	0.000492	0.000828	CcSEcCtD
Everolimus—Rash—Mesalazine—Crohn's disease	0.000488	0.000821	CcSEcCtD
Everolimus—Dermatitis—Mesalazine—Crohn's disease	0.000488	0.00082	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—TYK2—Crohn's disease	0.000488	0.00165	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—JAK2—Crohn's disease	0.000487	0.00165	CbGpPWpGaD
Everolimus—Headache—Mesalazine—Crohn's disease	0.000485	0.000816	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—TYK2—Crohn's disease	0.000485	0.00164	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—TYK2—Crohn's disease	0.000483	0.00163	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—STAT3—Crohn's disease	0.000481	0.00163	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—TYK2—Crohn's disease	0.00048	0.00163	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR9—Crohn's disease	0.00048	0.00162	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SLC11A1—Crohn's disease	0.000479	0.00162	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CCR6—Crohn's disease	0.000474	0.00161	CbGpPWpGaD
Everolimus—Vision blurred—Prednisone—Crohn's disease	0.000473	0.000796	CcSEcCtD
Everolimus—Ill-defined disorder—Prednisone—Crohn's disease	0.000466	0.000783	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—JAK2—Crohn's disease	0.000465	0.00157	CbGpPWpGaD
Everolimus—Anaemia—Prednisone—Crohn's disease	0.000464	0.00078	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—JAK2—Crohn's disease	0.000463	0.00157	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—JAK2—Crohn's disease	0.000463	0.00157	CbGpPWpGaD
Everolimus—Agitation—Prednisone—Crohn's disease	0.000461	0.000776	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—JAK2—Crohn's disease	0.000461	0.00156	CbGpPWpGaD
Everolimus—Nausea—Mesalazine—Crohn's disease	0.00046	0.000774	CcSEcCtD
Everolimus—Angioedema—Prednisone—Crohn's disease	0.000459	0.000772	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—JAK2—Crohn's disease	0.000458	0.00155	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	0.000458	0.00155	CbGpPWpGaD
Everolimus—Malaise—Prednisone—Crohn's disease	0.000453	0.000761	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—TYK2—Crohn's disease	0.000452	0.00153	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—TYK2—Crohn's disease	0.000452	0.00153	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—TYK2—Crohn's disease	0.000452	0.00153	CbGpPWpGaD
Everolimus—Syncope—Prednisone—Crohn's disease	0.00045	0.000757	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—TYK2—Crohn's disease	0.000448	0.00152	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GPR65—Crohn's disease	0.000446	0.00151	CbGpPWpGaD
Everolimus—MTOR—Disease—RSPO3—Crohn's disease	0.000444	0.0015	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—TYK2—Crohn's disease	0.000444	0.0015	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—TYK2—Crohn's disease	0.000442	0.0015	CbGpPWpGaD
Everolimus—Loss of consciousness—Prednisone—Crohn's disease	0.000441	0.000742	CcSEcCtD
Everolimus—Convulsion—Prednisone—Crohn's disease	0.000435	0.000732	CcSEcCtD
Everolimus—Hypertension—Prednisone—Crohn's disease	0.000433	0.000729	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—JAK2—Crohn's disease	0.000431	0.00146	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—JAK2—Crohn's disease	0.000431	0.00146	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JAK2—Crohn's disease	0.000431	0.00146	CbGpPWpGaD
Everolimus—Arthralgia—Prednisone—Crohn's disease	0.000427	0.000719	CcSEcCtD
Everolimus—Myalgia—Prednisone—Crohn's disease	0.000427	0.000719	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—JAK2—Crohn's disease	0.000427	0.00145	CbGpPWpGaD
Everolimus—Anxiety—Prednisone—Crohn's disease	0.000426	0.000716	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000424	0.000714	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—JAK2—Crohn's disease	0.000423	0.00143	CbGpPWpGaD
Everolimus—Discomfort—Prednisone—Crohn's disease	0.000422	0.00071	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—JAK2—Crohn's disease	0.000422	0.00143	CbGpPWpGaD
Everolimus—MTOR—Disease—SEL1L—Crohn's disease	0.000421	0.00143	CbGpPWpGaD
Everolimus—MTOR—Immune System—CARD9—Crohn's disease	0.000417	0.00141	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RBX1—Crohn's disease	0.000412	0.00139	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ACKR2—Crohn's disease	0.00041	0.00139	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HSPA1B—Crohn's disease	0.00041	0.00139	CbGpPWpGaD
Everolimus—FKBP1A—Disease—RBX1—Crohn's disease	0.00041	0.00139	CbGpPWpGaD
Everolimus—Oedema—Prednisone—Crohn's disease	0.00041	0.000689	CcSEcCtD
Everolimus—Infection—Prednisone—Crohn's disease	0.000407	0.000685	CcSEcCtD
Everolimus—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	0.000404	0.00137	CbGpPWpGaD
Everolimus—Shock—Prednisone—Crohn's disease	0.000403	0.000678	CcSEcCtD
Everolimus—Nervous system disorder—Prednisone—Crohn's disease	0.000402	0.000676	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—TYK2—Crohn's disease	0.0004	0.00135	CbGpPWpGaD
Everolimus—Tachycardia—Prednisone—Crohn's disease	0.0004	0.000673	CcSEcCtD
Everolimus—Skin disorder—Prednisone—Crohn's disease	0.000398	0.000669	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—IL6—Crohn's disease	0.000397	0.00135	CbGpPWpGaD
Everolimus—Hyperhidrosis—Prednisone—Crohn's disease	0.000396	0.000666	CcSEcCtD
Everolimus—Anorexia—Prednisone—Crohn's disease	0.000391	0.000657	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—MLN—Crohn's disease	0.000389	0.00132	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—IL6—Crohn's disease	0.000387	0.00131	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—Crohn's disease	0.000383	0.0013	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—JAK2—Crohn's disease	0.000382	0.00129	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—STAT3—Crohn's disease	0.00038	0.00128	CbGpPWpGaD
Everolimus—MTOR—Disease—LTF—Crohn's disease	0.000378	0.00128	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—UBE2D1—Crohn's disease	0.000376	0.00127	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Prednisone—Crohn's disease	0.000373	0.000628	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—STAT3—Crohn's disease	0.000373	0.00126	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—Crohn's disease	0.000373	0.00126	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—Crohn's disease	0.000373	0.00126	CbGpPWpGaD
Everolimus—Insomnia—Prednisone—Crohn's disease	0.000371	0.000623	CcSEcCtD
Everolimus—Paraesthesia—Prednisone—Crohn's disease	0.000368	0.000619	CcSEcCtD
Everolimus—MTOR—Innate Immune System—RIPK2—Crohn's disease	0.000365	0.00123	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—UBE2D1—Crohn's disease	0.000361	0.00122	CbGpPWpGaD
Everolimus—Dyspepsia—Prednisone—Crohn's disease	0.000361	0.000607	CcSEcCtD
Everolimus—FKBP1A—Disease—UBE2D1—Crohn's disease	0.00036	0.00122	CbGpPWpGaD
Everolimus—Decreased appetite—Prednisone—Crohn's disease	0.000356	0.000599	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—TAGAP—Crohn's disease	0.000356	0.0012	CbGpPWpGaD
Everolimus—Fatigue—Prednisone—Crohn's disease	0.000353	0.000594	CcSEcCtD
Everolimus—Constipation—Prednisone—Crohn's disease	0.00035	0.000589	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—ITGA4—Crohn's disease	0.00035	0.00119	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RIPK2—Crohn's disease	0.00035	0.00119	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RASGRP1—Crohn's disease	0.000344	0.00116	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—STAT3—Crohn's disease	0.000341	0.00116	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—Crohn's disease	0.00034	0.00115	CbGpPWpGaD
Everolimus—Feeling abnormal—Prednisone—Crohn's disease	0.000338	0.000568	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TAB1—Crohn's disease	0.000337	0.00114	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—Crohn's disease	0.000336	0.00114	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Prednisone—Crohn's disease	0.000335	0.000563	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NOD2—Crohn's disease	0.000331	0.00112	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—Crohn's disease	0.000331	0.00112	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RASGRP1—Crohn's disease	0.00033	0.00112	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD79A—Crohn's disease	0.000329	0.00111	CbGpPWpGaD
Everolimus—Abdominal pain—Prednisone—Crohn's disease	0.000324	0.000545	CcSEcCtD
Everolimus—Body temperature increased—Prednisone—Crohn's disease	0.000324	0.000545	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CCR6—Crohn's disease	0.000318	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—STAT3—Crohn's disease	0.000316	0.00107	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—Crohn's disease	0.000312	0.00106	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—SOCS1—Crohn's disease	0.000312	0.00106	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RSPO3—Crohn's disease	0.000311	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—Crohn's disease	0.00031	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—STAT3—Crohn's disease	0.000309	0.00105	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—TYK2—Crohn's disease	0.000308	0.00104	CbGpPWpGaD
Everolimus—MTOR—Disease—GCKR—Crohn's disease	0.000304	0.00103	CbGpPWpGaD
Everolimus—MTOR—Immune System—NOD1—Crohn's disease	0.000304	0.00103	CbGpPWpGaD
Everolimus—Hypersensitivity—Prednisone—Crohn's disease	0.000302	0.000508	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—SOCS1—Crohn's disease	0.000299	0.00101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SEL1L—Crohn's disease	0.000295	0.000998	CbGpPWpGaD
Everolimus—Asthenia—Prednisone—Crohn's disease	0.000294	0.000494	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—JAK2—Crohn's disease	0.000294	0.000994	CbGpPWpGaD
Everolimus—Pruritus—Prednisone—Crohn's disease	0.00029	0.000488	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—RBX1—Crohn's disease	0.000287	0.000972	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CXCL8—Crohn's disease	0.000286	0.000967	CbGpPWpGaD
Everolimus—Diarrhoea—Prednisone—Crohn's disease	0.00028	0.000471	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—Crohn's disease	0.00028	0.000949	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTGER4—Crohn's disease	0.00028	0.000947	CbGpPWpGaD
Everolimus—MTOR—Immune System—CCR6—Crohn's disease	0.000276	0.000935	CbGpPWpGaD
Everolimus—Dizziness—Prednisone—Crohn's disease	0.000271	0.000456	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCR9—Crohn's disease	0.00027	0.000913	CbGpPWpGaD
Everolimus—MTOR—Disease—SLC11A1—Crohn's disease	0.000269	0.000911	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—Crohn's disease	0.000265	0.000897	CbGpPWpGaD
Everolimus—Vomiting—Prednisone—Crohn's disease	0.000261	0.000438	CcSEcCtD
Everolimus—Rash—Prednisone—Crohn's disease	0.000258	0.000434	CcSEcCtD
Everolimus—Dermatitis—Prednisone—Crohn's disease	0.000258	0.000434	CcSEcCtD
Everolimus—FKBP1A—Disease—SMAD3—Crohn's disease	0.000257	0.000871	CbGpPWpGaD
Everolimus—Headache—Prednisone—Crohn's disease	0.000257	0.000432	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—Crohn's disease	0.000254	0.000859	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTPN2—Crohn's disease	0.000253	0.000855	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—UBE2D1—Crohn's disease	0.000252	0.000853	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GPR65—Crohn's disease	0.000251	0.000849	CbGpPWpGaD
Everolimus—MTOR—Immune System—RBX1—Crohn's disease	0.00025	0.000846	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—Crohn's disease	0.00025	0.000845	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RIPK2—Crohn's disease	0.000244	0.000827	CbGpPWpGaD
Everolimus—Nausea—Prednisone—Crohn's disease	0.000243	0.000409	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—IL6—Crohn's disease	0.000238	0.000807	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL3—Crohn's disease	0.000238	0.000806	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—IL6—Crohn's disease	0.000237	0.000803	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—Crohn's disease	0.000236	0.000799	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CRP—Crohn's disease	0.000235	0.000796	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—Crohn's disease	0.000235	0.000795	CbGpPWpGaD
Everolimus—MTOR—Disease—RBX1—Crohn's disease	0.000231	0.000781	CbGpPWpGaD
Everolimus—MTOR—Disease—HSPA1B—Crohn's disease	0.000231	0.000781	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RASGRP1—Crohn's disease	0.00023	0.00078	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—Crohn's disease	0.00023	0.000778	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR4—Crohn's disease	0.000225	0.000763	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—Crohn's disease	0.000221	0.000748	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—IL6—Crohn's disease	0.000221	0.000748	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—Crohn's disease	0.000221	0.000748	CbGpPWpGaD
Everolimus—MTOR—Immune System—UBE2D1—Crohn's disease	0.000219	0.000742	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—Crohn's disease	0.000219	0.000741	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—Crohn's disease	0.000217	0.000735	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—Crohn's disease	0.000216	0.000732	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—Crohn's disease	0.000216	0.00073	CbGpPWpGaD
Everolimus—MTOR—Immune System—RIPK2—Crohn's disease	0.000212	0.000719	CbGpPWpGaD
Everolimus—MTOR—Immune System—ITGA4—Crohn's disease	0.000212	0.000719	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SOCS1—Crohn's disease	0.000209	0.000707	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—ICAM1—Crohn's disease	0.000208	0.000702	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL3—Crohn's disease	0.000207	0.000701	CbGpPWpGaD
Everolimus—MTOR—Disease—UBE2D1—Crohn's disease	0.000202	0.000685	CbGpPWpGaD
Everolimus—MTOR—Immune System—RASGRP1—Crohn's disease	0.0002	0.000678	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD79A—Crohn's disease	0.0002	0.000676	CbGpPWpGaD
Everolimus—MTOR—Immune System—TAB1—Crohn's disease	0.000196	0.000664	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—Crohn's disease	0.000196	0.000663	CbGpPWpGaD
Everolimus—MTOR—Immune System—NOD2—Crohn's disease	0.000193	0.000652	CbGpPWpGaD
Everolimus—MTOR—Immune System—SOCS1—Crohn's disease	0.000182	0.000615	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SMAD3—Crohn's disease	0.00018	0.00061	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR6—Crohn's disease	0.000179	0.000605	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TYK2—Crohn's disease	0.000176	0.000594	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TYK2—Crohn's disease	0.000168	0.000568	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—JAK2—Crohn's disease	0.000168	0.000567	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2RA—Crohn's disease	0.000167	0.000565	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL18—Crohn's disease	0.000163	0.000553	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RBX1—Crohn's disease	0.000162	0.000547	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—Crohn's disease	0.000161	0.000543	CbGpPWpGaD
Everolimus—FKBP1A—Disease—JAK2—Crohn's disease	0.00016	0.000542	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—Crohn's disease	0.000159	0.000538	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTGER4—Crohn's disease	0.000157	0.000532	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—Crohn's disease	0.000152	0.000516	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—Crohn's disease	0.000152	0.000514	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—Crohn's disease	0.000151	0.00051	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—Crohn's disease	0.000151	0.00051	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2RA—Crohn's disease	0.000145	0.000491	CbGpPWpGaD
Everolimus—MTOR—Disease—SMAD3—Crohn's disease	0.000145	0.00049	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—UBE2D1—Crohn's disease	0.000142	0.00048	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RIPK2—Crohn's disease	0.000137	0.000465	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—Crohn's disease	0.000137	0.000463	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL3—Crohn's disease	0.000134	0.000453	CbGpPWpGaD
Everolimus—MTOR—Immune System—TLR4—Crohn's disease	0.000131	0.000444	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RASGRP1—Crohn's disease	0.00013	0.000439	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—Crohn's disease	0.000126	0.000426	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TYK2—Crohn's disease	0.000118	0.000398	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—Crohn's disease	0.000118	0.000398	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SOCS1—Crohn's disease	0.000117	0.000397	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	0.000113	0.000382	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JAK2—Crohn's disease	0.000112	0.00038	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—Crohn's disease	0.000102	0.000346	CbGpPWpGaD
Everolimus—MTOR—Immune System—TYK2—Crohn's disease	0.000102	0.000346	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMAD3—Crohn's disease	0.000101	0.000343	CbGpPWpGaD
Everolimus—MTOR—Immune System—JAK2—Crohn's disease	9.76e-05	0.00033	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTMR3—Crohn's disease	9.6e-05	0.000325	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNG—Crohn's disease	9.58e-05	0.000324	CbGpPWpGaD
Everolimus—MTOR—Disease—TYK2—Crohn's disease	9.44e-05	0.00032	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2RA—Crohn's disease	9.39e-05	0.000318	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—Crohn's disease	9.25e-05	0.000313	CbGpPWpGaD
Everolimus—MTOR—Disease—JAK2—Crohn's disease	9.01e-05	0.000305	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—Crohn's disease	8.59e-05	0.000291	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL1B—Crohn's disease	8.54e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—Crohn's disease	8.54e-05	0.000289	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—Crohn's disease	8.48e-05	0.000287	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—Crohn's disease	8.23e-05	0.000279	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—Crohn's disease	8.21e-05	0.000278	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FADS1—Crohn's disease	7.48e-05	0.000253	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—Crohn's disease	7.16e-05	0.000242	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX4—Crohn's disease	7e-05	0.000237	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCKR—Crohn's disease	6.76e-05	0.000229	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TYK2—Crohn's disease	6.61e-05	0.000224	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—Crohn's disease	6.61e-05	0.000224	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAK2—Crohn's disease	6.31e-05	0.000214	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—Crohn's disease	5.76e-05	0.000195	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—Crohn's disease	5.75e-05	0.000195	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—Crohn's disease	5e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—Crohn's disease	4.63e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—Crohn's disease	4.62e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—Crohn's disease	3.23e-05	0.000109	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—Crohn's disease	2.15e-05	7.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—Crohn's disease	1.88e-05	6.37e-05	CbGpPWpGaD
